JACC:血中酮体不仅会导致酮症,居然还会影响心肌梗死结局!

2021-09-30 MedSci原创 MedSci原创

心肌梗死(MI)仍然是心力衰竭(HF)发展的一个主要风险因素。

尽管过去几十年来死亡率和发病率不断下降,但心肌梗死(MI)仍然是心力衰竭(HF)发展的一个主要风险因素。HF的心肌代谢已被发现依赖于酮体(KBs)作为主要的细胞能量来源,参与KB氧化的酶相应上调,循环中的KB水平增加。

HF中血浆KBs的上调被认为是由神经激素因素如儿茶酚胺和钠尿肽的上调引起的肝脏生酮作用增加的结果。儿茶酚胺和钠尿肽都会刺激脂肪细胞的脂肪分解,并促进非酯化脂肪酸的释放,而非酯化脂肪酸是生酮的重要代谢前体。

然而,循环中的KBs在缺血/再灌注中的作用仍然未知。为了调查ST段抬高型心肌梗死(STEMI)患者的KBs的纵向变化及其与功能结局的关系,来自荷兰格罗宁根大学血管病的专家开展了相关研究,结果发表在JACC杂志上。

研究人员对来自STEMI后早期二甲双胍治疗随机试验的369名参与者进行KBs测量。在发病时、24小时后和4个月后,通过核磁共振光谱仪测量KBs(β-羟基丁酸、乙酰乙酸和丙酮)的非空腹血浆浓度。4个月后通过心脏磁共振成像确定心肌梗死的大小和左心室射血分数(LVEF)。使用多变量线性回归分析确定循环中的KBs与心肌梗死大小和左心室射血分数的关系。

结果显示,循环KBs在STEMI发病时很高(总KBs中位数:520 μmol/L;四分位数范围[IQR]:315-997 μmol/L)。再灌注后24小时,与4个月的随访水平相比,KBs仍然很高(分别为206 μmol/L [IQR: 174-246] vs 166 μmol/L [IQR: 143-201])。24小时内KB浓度的增加与心肌梗死面积的增大(总KBs,每100μmol/L:β = 1.56;95%置信区间:0.29-2.83)和LVEF的降低(β = -1.78;95%CI:(-3.17至-0.39)独立相关。

急性NSTEMI后血中酮体水平及其对预后的关系

综上,循环中的KBs在出现STEMI的患者中增加。24小时内较高的KBs与STEMI后的功能结果有关,这表明酮类代谢在应对心肌缺血中的潜在作用。

 

参考文献:

Association of Circulating Ketone Bodies With Functional Outcomes After ST-Segment Elevation Myocardial Infarction. J Am Coll Cardiol. 2021 Oct, 78 (14) 1421–1432

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1854993, encodeId=4cf318549937f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Oct 21 04:33:17 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641223, encodeId=05751641223c1, content=<a href='/topic/show?id=8d739553475' target=_blank style='color:#2F92EE;'>#酮症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95534, encryptionId=8d739553475, topicName=酮症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=790822763597, createdName=ms705947299214030, createdTime=Sun Mar 20 11:33:17 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190651, encodeId=bde81190651e8, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/949453D13700D5D5E2170BDB0CBBEB81/100, createdBy=66e32451407, createdName=胡国宏, createdTime=Mon Feb 07 07:50:13 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326864, encodeId=85c513268641b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Oct 02 13:33:17 CST 2021, time=2021-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056764, encodeId=05821056e6498, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Fri Oct 01 14:15:03 CST 2021, time=2021-10-01, status=1, ipAttribution=)]
    2021-10-21 hbwxf
  2. [GetPortalCommentsPageByObjectIdResponse(id=1854993, encodeId=4cf318549937f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Oct 21 04:33:17 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641223, encodeId=05751641223c1, content=<a href='/topic/show?id=8d739553475' target=_blank style='color:#2F92EE;'>#酮症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95534, encryptionId=8d739553475, topicName=酮症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=790822763597, createdName=ms705947299214030, createdTime=Sun Mar 20 11:33:17 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190651, encodeId=bde81190651e8, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/949453D13700D5D5E2170BDB0CBBEB81/100, createdBy=66e32451407, createdName=胡国宏, createdTime=Mon Feb 07 07:50:13 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326864, encodeId=85c513268641b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Oct 02 13:33:17 CST 2021, time=2021-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056764, encodeId=05821056e6498, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Fri Oct 01 14:15:03 CST 2021, time=2021-10-01, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1854993, encodeId=4cf318549937f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Oct 21 04:33:17 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641223, encodeId=05751641223c1, content=<a href='/topic/show?id=8d739553475' target=_blank style='color:#2F92EE;'>#酮症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95534, encryptionId=8d739553475, topicName=酮症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=790822763597, createdName=ms705947299214030, createdTime=Sun Mar 20 11:33:17 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190651, encodeId=bde81190651e8, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/949453D13700D5D5E2170BDB0CBBEB81/100, createdBy=66e32451407, createdName=胡国宏, createdTime=Mon Feb 07 07:50:13 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326864, encodeId=85c513268641b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Oct 02 13:33:17 CST 2021, time=2021-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056764, encodeId=05821056e6498, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Fri Oct 01 14:15:03 CST 2021, time=2021-10-01, status=1, ipAttribution=)]
    2022-02-07 胡国宏
  4. [GetPortalCommentsPageByObjectIdResponse(id=1854993, encodeId=4cf318549937f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Oct 21 04:33:17 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641223, encodeId=05751641223c1, content=<a href='/topic/show?id=8d739553475' target=_blank style='color:#2F92EE;'>#酮症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95534, encryptionId=8d739553475, topicName=酮症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=790822763597, createdName=ms705947299214030, createdTime=Sun Mar 20 11:33:17 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190651, encodeId=bde81190651e8, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/949453D13700D5D5E2170BDB0CBBEB81/100, createdBy=66e32451407, createdName=胡国宏, createdTime=Mon Feb 07 07:50:13 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326864, encodeId=85c513268641b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Oct 02 13:33:17 CST 2021, time=2021-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056764, encodeId=05821056e6498, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Fri Oct 01 14:15:03 CST 2021, time=2021-10-01, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1854993, encodeId=4cf318549937f, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Thu Oct 21 04:33:17 CST 2021, time=2021-10-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1641223, encodeId=05751641223c1, content=<a href='/topic/show?id=8d739553475' target=_blank style='color:#2F92EE;'>#酮症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95534, encryptionId=8d739553475, topicName=酮症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=790822763597, createdName=ms705947299214030, createdTime=Sun Mar 20 11:33:17 CST 2022, time=2022-03-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1190651, encodeId=bde81190651e8, content=<a href='/topic/show?id=23e3454e353' target=_blank style='color:#2F92EE;'>#学习#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=45, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=45473, encryptionId=23e3454e353, topicName=学习)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/949453D13700D5D5E2170BDB0CBBEB81/100, createdBy=66e32451407, createdName=胡国宏, createdTime=Mon Feb 07 07:50:13 CST 2022, time=2022-02-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326864, encodeId=85c513268641b, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Sat Oct 02 13:33:17 CST 2021, time=2021-10-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1056764, encodeId=05821056e6498, content=谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cfc84293490, createdName=13f0c37dm61暂无昵称, createdTime=Fri Oct 01 14:15:03 CST 2021, time=2021-10-01, status=1, ipAttribution=)]
    2021-10-01 13f0c37dm61暂无昵称

    谢谢分享

    0

相关资讯

新版UA/NSTEMI诊疗指南 抗血小板及抗凝治疗更新点

  2011年3月28日,美国心脏病学会(ACC)/美国心脏学会(AHA)对《2007版不稳定性心绞痛(UA)和非ST段抬高心肌梗死(NSTEMI)诊疗指南》进行了更新,并在线发表于《美国心脏病学会杂志》(J Am Coll Cardiol)。指南修订重点在于为抗血小板和抗凝治疗提供更深入指导,下文是部分修订建议的总结。         抗血小板及华法林治疗

拓展阅读

Cardiovasc Diabetol:急性心肌梗死后酮体水平及其与心脏标志物的关系

与安慰剂相比,SGLT2i增加了AMI后3-βOHB水平。在随访中,较高的基线3-βOHB水平与心功能呈负相关,而随着时间的推移,3-βOHB水平持续增加可改善这些指标。

Heliyon:右心室衰竭中的酮体:独特的治疗机会

在伴随RVF的肺动脉高压(PAH)患者中,生酮反应受到抑制。在MCT介导的PAH引起的RVF大鼠模型中,膳食诱导的酮症改善了RV功能,抑制了NLRP3炎症小体激活,并抵抗了RV纤维化。

JAHA:血浆酮体水平升高与老年人全因死亡率和心力衰竭发生率相关

在美国老年人群中,较高的酮体浓度可预测心力衰竭和全因死亡率,且独立于代谢和心血管混杂因素。这种关联表明酮体代谢与衰老之间存在潜在的关系。

JAHA:酮体对肺动脉高压患者血流动力学的影响

发现 3-羟基丁酸 (3-OHB)  对PAH或CTEPH患者的血液动力学有积极影响。

Eur Heart J:循环酮体水平与心血管结局关系

以社区为基础的健康人群中内源性酮体的升高与较高的心血管疾病发病率和死亡率相关。酮体可作为心血管风险评估的潜在生物标志物。

JACC:ST段抬高心肌梗死患者的循环酮体水平越高,预后可能越差!

ST段抬高心肌梗死患者的循环酮体水平越高,预后可能越差!